AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) announced on November 12, 2026, that its wholly owned subsidiary, NeuralCloud Solutions Inc., has entered into a non-binding agreement with MyCor360+, a cardiac monitoring technology initiative, to explore integrating NeuralCloud's proprietary MaxYield™ ECG signal-processing technology into a next-generation cardiac monitoring device. The proposed collaboration aims to combine MyCor360+'s developing cellular-enabled hardware with NeuralCloud's AI-powered signal-processing capabilities for clinical applications. The agreement is non-binding, and no definitive commercial arrangement has been confirmed.

Key Points

  • AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) via subsidiary NeuralCloud Solutions Inc.
  • NeuralCloud signed a non-binding agreement with MyCor360+ to explore licensing and integrating MaxYield™ into a cardiac monitoring device under development
  • The proposed device is designed for up to 14 days of cardiac recording with automated cellular data transmission; neither MaxYield™ nor the MyCor360+ device has received FDA clearance for the proposed application
  • Investors may be watching whether the parties reach a definitive software licensing agreement, subject to technical development and regulatory requirements

MaxYield™ as the Software Intelligence Layer in MyCor360+'s Developing Platform

Under the proposed arrangement, MaxYield™ would serve as the AI-powered signal-processing engine embedded within MyCor360+'s cardiac monitoring hardware. MaxYield™ is designed to improve signal clarity, reduce noise and artifacts, and identify key ECG waveform components including P waves, QRS complexes, and T waves. The platform generates structured, machine-readable outputs — including waveform delineation and beat-level interval measurements — intended to support downstream ECG analysis and reporting workflows. MyCor360+ would oversee device development and commercialisation through its manufacturing partner.

MyCor360+ Device Design: Disposable Hardware with Cellular ECG Transmission

MyCor360+ is developing a cellular-enabled cardiac monitoring device intended to support both traditional Holter monitoring and mobile cardiac telemetry applications. The proposed device is being designed as a disposable, single-use solution capable of recording cardiac activity for up to 14 days, with automated ECG data transmission via cellular networks. Where connectivity is temporarily unavailable, the system is being designed to retain data for later transmission. The platform would also include a clinician-facing portal to support integration with existing healthcare workflows and electronic medical record systems, the release states.

NeuralCloud's Approach to Partnering with Medical Device Developers

The release states that NeuralCloud's broader strategy involves expanding the reach of MaxYield™ through partnerships with medical device developers, original equipment manufacturers, and cardiac monitoring technology providers. Rather than requiring hardware manufacturers to independently develop ECG signal-processing algorithms, MaxYield™ is designed as an AI-powered software layer that can be incorporated into compatible devices. This approach allows NeuralCloud to focus on ECG signal interpretation while collaborating with partners responsible for hardware development, manufacturing, and distribution, according to the announcement.

Regulatory Requirements and Early-Stage Status of the Collaboration

The collaboration remains at an early stage. Neither MaxYield™ nor the MyCor360+ device has received FDA clearance for the proposed application, and any definitive commercial arrangement or product commercialisation is subject to further agreement, successful technical integration, and applicable regulatory requirements. The parties intend to pursue a definitive software licensing agreement following further technical development and satisfaction of applicable regulatory requirements. The announcement does not constitute regulatory clearance, marketing authorisation, or a commitment to commercial deployment.